Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | HTR4 | Q13639 | 8/20 | 0.34 |
| ▸ | HTR2A | P28223 | 5/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6744650 | 0.83 | PTGER3 (0.41) | PTGER3HDAC8L3MBTL1KMO | |
| SCHEMBL6741094 | 0.80 | BRD4 (0.38) | PTGER3L3MBTL1KMOADRA1DADRA1A | |
| SCHEMBL15687398 | 0.75 | KMO (0.45) | PTGER3HDAC8KMOHTR4HTR2A | |
| SCHEMBL30174486 | 0.75 | KMO (0.45) | PTGER3HDAC8KMOHTR4HTR2A | |
| SCHEMBL12327554 | 0.73 | HDAC8 (0.53) | PTGER3HDAC8KMOHTR4HTR2A | |
| SCHEMBL6743454 | 0.73 | HRH3 (0.39) | PTGER3HDAC8KMOSIGMAR1 | |
| SCHEMBL6745988 | 0.73 | PTGER3 (0.37) | PTGER3HDAC8KMOHTR2ACACNA1H | |
| SCHEMBL20942425 | 0.72 | HDAC8 (0.43) | PTGER3HDAC8KMOHTR4HTR2A | |
| SCHEMBL6746545 | 0.72 | SIGMAR1 (0.48) | SIGMAR1KCNH2 | |
| SCHEMBL6740845 | 0.71 | HRH3 (0.40) | PTGER3HDAC8KMOADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-08-26 | — | — | US | disclosed |
| US-6716837-B1 | INDOLE AND INDAZOLE COMPOUNDS | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | SCN7A, CNR2, HTR7 | PTGER3 49/4885HDAC8 428/4885L3MBTL1 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.